Climb Bio to Present at Upcoming Investor Conferences
Get Alerts CLYM Hot Sheet
Join SI Premium – FREE
WELLESLEY, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced that members of its executive team are scheduled to participate in the upcoming investor conferences detailed below.
Guggenheim Securities Healthcare Innovation Conference
Format: Fireside chat and one-on-one investor meetings
Date: November 11-12, 2024
Stifel 2024 Healthcare Conference
Format: Fireside chat and one-on-one investor meetings
Date: November 18-19, 2024
36th Annual Piper Sandler Healthcare Conference
Format: Fireside chat and one-on-one investor meetings
Date: December 3-5, 2024
7th Annual Evercore ISI HealthCONx Conference
Format: Fireside chat and one-on-one investor meetings
Date: December 3-5, 2024
The presentations will be webcast live and available for replay under “News & Events” in the Investors section of the Company's website at climbbio.com.
About Climb Bio, Inc.
Climb Bio, Inc., is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. For more information, please visit climbbio.com.
Investors
Chris Brinzey
ICR Healthcare
[email protected]
339-970-2843
Media
Jon Yu
ICR Healthcare
[email protected]
475-395-5375
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate
- From Whitelist to the Next Meme Wave: Apeing Eyes the Best Meme Coin Spot While Snek and Pepe Hold Their Ground
- Best Crypto Presale: AlphaPepe Nears $2.5M as Buyers Race the August 26 Presale Closure Timeline
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Stifel, GuggenheimSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share